ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO913

Outcomes in CKD Patients With COVID-19

Session Information

  • COVID-19: Long COVID
    November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Wang, Lucas, Methodist Dallas Medical Center, Dallas, Texas, United States
  • Canela, Victor A., Methodist Dallas Medical Center, Dallas, Texas, United States
  • Sidhu, Manavjot, Methodist Dallas Medical Center, Dallas, Texas, United States

Chronic kidney disease (CKD) and End-stage renal disease patients are at increased risk of severe disease and worse outcomes in coronavirus disease 2019 (COVID-19). In this study, we compared outcomes, including rates of hospital mortality, major adverse cardiovascular events (MACE) and respiratory failure requiring mechanical ventilation in unvaccinated COVID-19 patients with established CKD/ESRD to COVID-19 patients with baseline normal kidney function.


Using an observational database, we analyzed 3183 unvaccinated hospitalized COVID-19 PCR-positive patients at Methodist Health System (Dallas, TX) from March 2020 to December 2020. The primary endpoint was all-cause in-hospital mortality. Severe disease was identified as any patient with a major adverse cardiovascular event (MACE) or respiratory failure requiring mechanical ventilation. A MACE was defined as congestive heart failure (CHF) exacerbation, myocardial infarction, stroke, pulmonary embolism, deep venous thrombosis, or shock. Chi-square (X2), Fischer’s exact test, and odds ratio tests were used to analyze observed variables.


Of the 3183 COVID-19 patients, 476 (15%) had pre-existing kidney disease (either CKD or ESRD), 170 (5.4%) were dialysis-dependent and 279 (8.79%) were CKD KDIGO stages 1-5. Compared to the non-CKD group, the CKD/ESRD group had an increased risk of all-cause in-hospital mortality (OR = 1.41, 95% CI = 1.04-1.83, p < 0.04). CKD/ESRD patients also had increased risk of MACE (OR = 1.24, 95% CI = 1.03-1.48, p < 0.02), specifically, higher risk of CHF exacerbation (OR = 3.28, 95% CI = 2.16-4.97, p < 0.001) and shock (OR = 1.36, 95% CI 1.01-1.84, p < 0.04). The risk of respiratory failure requiring mechanical ventilation was comparable between the CKD/ESRD and non-CKD cohorts (OR = 1.06, 95% CI 0.78-1.44, p = 0.70).


The COVID-19 pandemic had worldwide devastating outcomes for vulnerable groups such as CKD patients. In our study, we demonstrated that CKD and ESRD is associated with a higher incidence of mortality and MACE in COVID-19. By understanding the clinical course of these patients, clinicians may better anticipate and attempt to improve outcomes during inpatient visits.